Danaher Co. (NYSE:DHR) Shares Purchased by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. lifted its holdings in Danaher Co. (NYSE:DHR) by 3.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,272 shares of the conglomerate’s stock after acquiring an additional 462 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Danaher were worth $3,564,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Alpine Global Management LLC acquired a new position in shares of Danaher in the 3rd quarter valued at $1,489,000. Townsquare Capital LLC increased its stake in Danaher by 15.6% during the 3rd quarter. Townsquare Capital LLC now owns 9,524 shares of the conglomerate’s stock worth $2,363,000 after buying an additional 1,288 shares during the period. Creative Planning grew its stake in Danaher by 14.9% during the 3rd quarter. Creative Planning now owns 107,895 shares of the conglomerate’s stock worth $26,769,000 after purchasing an additional 13,987 shares in the last quarter. Tompkins Financial Corp lifted its stake in Danaher by 6.5% in the third quarter. Tompkins Financial Corp now owns 29,613 shares of the conglomerate’s stock worth $7,347,000 after acquiring an additional 1,796 shares during the last quarter. Finally, Hohimer Wealth Management LLC purchased a new position in Danaher in the third quarter valued at $2,846,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. TD Cowen boosted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Barclays lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Bank of America upped their target price on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Finally, Robert W. Baird raised their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $268.67.

Danaher Price Performance

NYSE DHR traded up $4.07 on Thursday, reaching $246.27. The company’s stock had a trading volume of 2,793,164 shares, compared to its average volume of 2,861,466. The stock has a market cap of $182.41 billion, a PE ratio of 41.05, a PEG ratio of 3.68 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $269.11. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The firm’s 50 day moving average is $255.06 and its two-hundred day moving average is $247.32.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.36 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s payout ratio is currently 18.31%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at approximately $7,457,798.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock worth $37,536,717 in the last quarter. 10.90% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.